Paraplegia News and Research

RSS
Paraplegia is an impairment in motor or sensory function of the lower extremities. It is usually the result of spinal cord injury or a congenital condition such as spina bifida which affects the neural elements of the spinal canal.
Neuralstem ends litigation with ReNeuron

Neuralstem ends litigation with ReNeuron

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

Neuralstem updates Phase I human clinical trial of spinal cord stem cells for ALS

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Novel Compound's NVC-422 broad-spectrum antimicrobial agent kills P. mirabilis bacteria in catheters

Study on spinal cord stem cells paves way for post stroke symptom treatment

Study on spinal cord stem cells paves way for post stroke symptom treatment

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Benefits of drug L-methionine for neurogenic bladder disorders unclear

Benefits of drug L-methionine for neurogenic bladder disorders unclear

Medtronic launches educational campaign to promote awareness on spasticity

Medtronic launches educational campaign to promote awareness on spasticity

Neuralstem announces completion of $10 million registered direct offering

Neuralstem announces completion of $10 million registered direct offering

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

Neuralstem signs definitive agreements to sell $10M of units in registered-direct offering

New study data on distal aortic perfusion for thoracoabdominal aortic aneurysm repair

New study data on distal aortic perfusion for thoracoabdominal aortic aneurysm repair

Neuralstem updates progress of ongoing Phase I human clinical trial for ALS

Neuralstem updates progress of ongoing Phase I human clinical trial for ALS

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Neuralstem raises $5.25M, also receives NYSE Amex compliance notice

Neuralstem raises $5.25M, also receives NYSE Amex compliance notice

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells